Curated Information

Javascript is not enabled on this browser. This site will not work properly without Javascript.

Home

Curated Information Page

PubMed Id: 17567956

This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus^®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus^®, click here.

Information from this record has been curated, but not yet edited in PhosphoSitePlus^® and may be incomplete.

Dulyaninova NG, House RP, Betapudi V, Bresnick AR (2007) Myosin-IIA heavy-chain phosphorylation regulates the motility of MDA-MB-231 carcinoma cells. Mol Biol Cell 18, 3144-55 17567956

Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.

T19-p - MRLC2 (human)

▲

Orthologous residues

MRLC2 (human): T19‑p, MRLC2 (mouse): T19‑p, MRLC2 (rat): T19‑p, MRLC2 (cow): T19‑p

Characterization

Methods used to characterize site in vivo: phospho-antibody, western blotting

Disease tissue studied: breast cancer

Relevant cell lines - cell types - tissues: MDA-MB231 (breast cell)

Cellular systems studied: cell lines

Species studied: human

Upstream Regulation

Treatments, proteins and their effect on site modification:

Treatments	Referenced Treatments	Manipulated Protein	Referenced Protein	Effect	Notes
EGF				increase

S20-p - MRLC2 (human)

▲

Orthologous residues

MRLC2 (human): S20‑p, MRLC2 (mouse): S20‑p, MRLC2 (rat): S20‑p, MRLC2 (cow): S20‑p

Characterization

Methods used to characterize site in vivo: phospho-antibody, western blotting

Disease tissue studied: breast cancer

Relevant cell lines - cell types - tissues: MDA-MB231 (breast cell)

Cellular systems studied: cell lines

Species studied: human

Upstream Regulation

Treatments, proteins and their effect on site modification:

Treatments	Referenced Treatments	Manipulated Protein	Referenced Protein	Effect	Notes
EGF				increase

S1916-p - MYH9 (human)

▲

Orthologous residues

MYH9 (human): S1916‑p, MYH9 (mouse): S1916‑p, MYH9 (rat): S1917‑p

Characterization

Methods used to characterize site in vivo: immunoprecipitation, phosphoamino acid analysis, western blotting

Disease tissue studied: breast cancer

Relevant cell lines - cell types - tissues: MDA-MB231 (breast cell)

Cellular systems studied: cell lines

Species studied: human

Enzymes shown to modify site in vitro:

Type	Enzyme
KINASE	PKCA (human)

Upstream Regulation

Treatments, proteins and their effect on site modification:

Treatments	Referenced Treatments	Manipulated Protein	Referenced Protein	Effect	Notes
EGF				increase

S1943-p - MYH9 (human)

▲

Orthologous residues

MYH9 (human): S1943‑p, MYH9 (mouse): S1943‑p, MYH9 (rat): S1944‑p

Characterization

Methods used to characterize site in vivo: immunoprecipitation, mutation of modification site, phospho-antibody, phosphoamino acid analysis, western blotting

Disease tissue studied: breast cancer

Relevant cell lines - cell types - tissues: MDA-MB231 (breast cell)

Cellular systems studied: cell lines

Species studied: human

Enzymes shown to modify site in vitro:

Type	Enzyme
KINASE	CK2-A1 (human)

Upstream Regulation

Treatments, proteins and their effect on site modification:

Treatments	Referenced Treatments	Manipulated Protein	Referenced Protein	Effect	Notes
EGF				increase

Downstream Regulation

Effect of modification (process): cell motility, altered, cytoskeletal reorganization

Modification regulates interactions with:

Interacting molecule	Interacting domains	Effect	Consequences (function)	Consequences (process)	Detection assays
S100A4 (human)		Disrupts			in vitro

Home \| Curator Login	With enhanced literature mining using Linguamatics I2E		Produced by 3rd Millennium \| Design by Digizyme
			©2003-2013 Cell Signaling Technology, Inc.